Advertisement

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Opportunities to Optimize Cancer Policies Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Jul
17
Today In Oncology
Node-Negative Breast Cancer 20-Year Outcomes With IM-MS Lymph Node Irradiation
Virtual Sustained Counseling and Tobacco Treatment Improve Quit Rates for Patients With Cancer in Community Settings
Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
Digital Check-ins May Improve Outcomes in Patients Undergoing Treatment for Advanced Cancer
How Do Surgical Ovarian Cancer Prevention Strategies Compare for Sexual Function?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo